Mounjaro vs. Ozempic: Which GLP-1 Drug Is Right for You?

<p>Mounjaro and Ozempic are two of the most prescribed injectable medications in the United States — and the most frequently compared. Both are once-weekly injections approved for type 2 diabetes, both belong to the GLP-1 receptor agonist class, and both have become household names in the conversation about weight management. Yet they are fundamentally different drugs, and choosing between them involves more than picking the one with the better commercial.</p> <p>This guide breaks down every meaningful difference between Mounjaro (tirzepatide) and Ozempic (semaglutide) — mechanism of action, clinical trial results, dosing, cost, insurance coverage, and side effects — so you can have an informed conversation with your doctor about which option makes sense for your situation.</p> <h2>The Core Difference: Dual Agonist vs. Single Agonist</h2> <p>The most important distinction between these two drugs is pharmacological. <strong>Ozempic (semaglutide)</strong> is a <em>GLP-1 receptor agonist</em> — it mimics the glucagon-like peptide-1 hormone, which stimulates insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. This single mechanism is well-established and has been validated across more than a decade of clinical trials.</p> <p><strong>Mounjaro (tirzepatide)</strong> is a <em>dual GIP/GLP-1 receptor agonist</em> — the first of its kind. In addition to activating GLP-1 receptors, it also activates receptors for glucose-dependent insulinotropic polypeptide (GIP), a second gut hormone involved in insulin secretion and fat metabolism. This dual mechanism appears to produce synergistic effects on both blood sugar control and weight loss that exceed what GLP-1 activation alone can achieve.</p> <p>In practical terms: both drugs work, both are effective, and both are administered the same way (once weekly subcutaneous injection). But the clinical trial data consistently shows that tirzepatide produces greater weight loss than semaglutide at equivalent time points.</p> <h2>Head-to-Head Comparison Table</h2> <table> <thead> <tr> <th>Feature</th> <th>Mounjaro (Tirzepatide)</th> <th>Ozempic (Semaglutide)</th> </tr> </thead> <tbody> <tr> <td><strong>Manufacturer</strong></td> <td>Eli Lilly</td> <td>Novo Nordisk</td> </tr> <tr> <td><strong>Active Ingredient</strong></td> <td>Tirzepatide</td> <td>Semaglutide</td> </tr> <tr> <td><strong>Mechanism</strong></td> <td>Dual GIP + GLP-1 receptor agonist</td> <td>GLP-1 receptor agonist only</td> </tr> <tr> <td><strong>FDA Approval</strong></td> <td>Type 2 diabetes (2022)</td> <td>Type 2 diabetes (2017); cardiovascular risk reduction (2023)</td> </tr> <tr> <td><strong>Weight Loss Approval</strong></td> <td>Zepbound (tirzepatide) — FDA approved for obesity (2023)</td> <td>Wegovy (semaglutide) — FDA approved for obesity (2021)</td> </tr> <tr> <td><strong>Doses Available</strong></td> <td>2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg</td> <td>0.25 mg, 0.5 mg, 1 mg, 2 mg</td> </tr> <tr> <td><strong>Starting Dose</strong></td> <td>2.5 mg/week × 4 weeks, then 5 mg/week</td> <td>0.25 mg/week × 4 weeks, then 0.5 mg/week</td> </tr> <tr> <td><strong>Max Dose</strong></td> <td>15 mg/week</td> <td>2 mg/week</td> </tr> <tr> <td><strong>Administration</strong></td> <td>Once-weekly subcutaneous injection</td> <td>Once-weekly subcutaneous injection</td> </tr> <tr> <td><strong>Average Weight Loss (trials)</strong></td> <td>15–22.5% body weight (SURMOUNT-1)</td> <td>9.6–14.9% body weight (STEP-1/SUSTAIN)</td> </tr> <tr> <td><strong>A1C Reduction</strong></td> <td>1.9–2.6% (SURPASS trials)</td> <td>1.5–1.8% (SUSTAIN trials)</td> </tr> <tr> <td><strong>Cardiovascular Benefit</strong></td> <td>Pending (SURPASS-CVOT ongoing)</td> <td>Proven — reduces MACE in high-risk patients (SUSTAIN-6)</td> </tr> <tr> <td><strong>List Price (monthly)</strong></td> <td>~$1,112/month</td> <td>~$980/month</td> </tr> <tr> <td><strong>With Commercial Insurance Savings Card</strong></td> <td>As low as $25/month</td> <td>As low as $25/month (introductory); $199/month ongoing</td> </tr> <tr> <td><strong>Self-Pay / Uninsured Option</strong></td> <td>LillyDirect vials from $499/month</td> <td>NovoCare self-pay: $349/month (0.5–1 mg), $499/month (2 mg)</td> </tr> <tr> <td><strong>Generic Available</strong></td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Common Side Effects</strong></td> <td>Nausea, diarrhea, vomiting, constipation</td> <td>Nausea, diarrhea, vomiting, constipation</td> </tr> <tr> <td><strong>Black Box Warning</strong></td> <td>Thyroid C-cell tumors (rodent studies)</td> <td>Thyroid C-cell tumors (rodent studies)</td> </tr> <tr> <td><strong>Oral Version Available</strong></td> <td>No</td> <td>Yes — Rybelsus (oral semaglutide, 3–14 mg/day)</td> </tr> </tbody> </table> <h2>Clinical Trial Results: What the Data Shows</h2> <p>The most compelling evidence for the difference between these two drugs comes from two sources: the SURPASS and SURMOUNT trial programs for tirzepatide, and the SUSTAIN and STEP trial programs for semaglutide.</p> <h3>Weight Loss</h3> <p>In the SURMOUNT-1 trial — the landmark obesity trial for tirzepatide — participants without diabetes lost <strong>16.0%, 21.4%, and 22.5%</strong> of body weight at doses of 5 mg, 10 mg, and 15 mg respectively over 72 weeks. The 22.5% figure at the highest dose was unprecedented for a non-surgical weight loss intervention at the time of publication.</p> <p>By comparison, the STEP-1 trial for semaglutide 2.4 mg (the Wegovy dose) showed a mean weight loss of <strong>14.9%</strong> over 68 weeks in adults with obesity. This is a meaningful result — but tirzepatide's 15 mg dose produced roughly 50% more weight loss in comparable populations.</p> <p>A 2024 NEJM head-to-head trial (SURMOUNT-5) confirmed this gap directly: at 72 weeks, tirzepatide produced superior weight loss and waist circumference reduction compared to semaglutide 2.4 mg in adults with obesity. Real-world data from Truveta's registry study found tirzepatide users lost up to three times more weight than semaglutide users at 6 months.</p> <h3>Blood Sugar Control</h3> <p>For type 2 diabetes management, both drugs are highly effective. The SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes: tirzepatide at all three doses (5 mg, 10 mg, 15 mg) produced significantly greater A1C reductions than semaglutide 1 mg. Mean A1C reductions ranged from <strong>2.01% to 2.30%</strong> with tirzepatide vs. <strong>1.86%</strong> with semaglutide.</p> <h3>Cardiovascular Protection</h3> <p>This is where Ozempic holds a meaningful advantage. The SUSTAIN-6 trial demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — in patients with type 2 diabetes and established cardiovascular disease. This cardiovascular indication was formally added to Ozempic's FDA label in 2023.</p> <p>Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of 2026. Until those results are published, semaglutide has the stronger evidence base for patients whose primary concern is heart disease prevention alongside diabetes management.</p> <h2>Cost Comparison in 2026</h2> <p>Both drugs carry high list prices, but manufacturer savings programs make them accessible for most commercially insured patients. The self-pay landscape is more nuanced.</p> <h3>Mounjaro Pricing</h3> <p>The list price for Mounjaro is <strong>$1,112.16 per monthly fill</strong> regardless of dose. Eli Lilly's savings card reduces this to <strong>as low as $25/month</strong> for eligible patients with commercial insurance. For uninsured or self-paying patients, Eli Lilly's LillyDirect program offers tirzepatide vials starting at <strong>$499/month</strong> — the same molecule as Mounjaro but in a vial format rather than the auto-injector pen.</p> <p>For a detailed breakdown of Mounjaro prices by pharmacy and dose, see our <a href="/blog/mounjaro-cost-without-insurance">Mounjaro Cost Without Insurance guide</a>.</p> <h3>Ozempic Pricing</h3> <p>Ozempic's list price is approximately <strong>$980/month</strong>. Novo Nordisk's savings card offers an introductory rate of <strong>$199/month</strong> for new patients (first two fills), then $349/month for the 0.5 mg and 1 mg doses and $499/month for the 2 mg dose. For uninsured patients, the NovoCare Pharmacy self-pay program offers the same rates: $349/month for lower doses and $499/month for the 2 mg dose.</p> <p>For a full breakdown of Ozempic prices, see our <a href="/blog/ozempic-cost-without-insurance">Ozempic Cost Without Insurance guide</a>.</p> <h3>Savings Card Summary</h3> <table> <thead> <tr> <th>Scenario</th> <th>Mounjaro</th> <th>Ozempic</th> </tr> </thead> <tbody> <tr> <td>With commercial insurance + savings card</td> <td>As low as $25/month</td> <td>$25 intro (2 fills), then $199–$349/month</td> </tr> <tr> <td>Self-pay / uninsured (brand pen)</td> <td>~$1,112/month</td> <td>$349–$499/month (NovoCare)</td> </tr> <tr> <td>Self-pay / uninsured (vials)</td> <td>$499/month (LillyDirect)</td> <td>Not available in vial format</td> </tr> <tr> <td>Medicare Part D</td> <td>Covered; cost varies by plan</td> <td>Covered; cost varies by plan</td> </tr> <tr> <td>Medicaid</td> <td>Coverage varies by state</td> <td>Coverage varies by state</td> </tr> </tbody> </table> <p>Use our <a href="/savings">free RxGo savings tool</a> to compare real-time prices at pharmacies near you for both Mounjaro and Ozempic.</p> <h2>Side Effects: Are They Different?</h2> <p>The side effect profiles of Mounjaro and Ozempic are broadly similar, reflecting their shared GLP-1 mechanism. The most common side effects for both drugs are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are most pronounced during dose escalation and typically improve over time as the body adjusts.</p> <p>Both drugs carry the same black box warning regarding thyroid C-cell tumors, based on rodent studies. Neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).</p> <p>Some studies suggest that tirzepatide's dual mechanism may produce a slightly different tolerability profile than semaglutide — with some patients reporting less nausea on tirzepatide at equivalent weight-loss doses. However, head-to-head tolerability data is limited, and individual responses vary significantly. Both drugs require a slow titration schedule precisely to minimize GI side effects.</p> <h2>Which Drug Is Right for You?</h2> <p>The answer depends on your primary treatment goal and medical history:</p> <p><strong>Choose Mounjaro (tirzepatide) if:</strong> your primary goal is maximum weight loss, you have type 2 diabetes and want the strongest A1C reduction available, or you are uninsured and can access LillyDirect vials at $499/month. The clinical evidence consistently shows tirzepatide produces greater weight loss than semaglutide at equivalent time points.</p> <p><strong>Choose Ozempic (semaglutide) if:</strong> you have established cardiovascular disease and need proven MACE reduction (the SUSTAIN-6 benefit is well-documented), you prefer an oral option (Rybelsus is oral semaglutide), or your insurance plan covers Ozempic but not Mounjaro. Ozempic also has a longer track record — it has been on the market since 2017 vs. Mounjaro's 2022 approval.</p> <p>It is worth noting that neither Mounjaro nor Ozempic is FDA-approved for weight loss — that indication belongs to their sister drugs, <a href="/blog/zepbound-cost-without-insurance">Zepbound (tirzepatide)</a> and <a href="/blog/wegovy-cost-without-insurance">Wegovy (semaglutide)</a> respectively. However, both are commonly prescribed off-label for weight management in patients who also have type 2 diabetes.</p> <h2>How to Save on Either Drug</h2> <p>Regardless of which drug your doctor prescribes, there are several reliable ways to reduce your out-of-pocket cost:</p> <p><strong>1. Use the manufacturer savings card.</strong> Both Eli Lilly (Mounjaro) and Novo Nordisk (Ozempic) offer savings cards that can reduce monthly costs to $25–$199 for commercially insured patients. Apply at <a href="https://mounjaro.lilly.com/savings-resources" target="_blank" rel="noopener">mounjaro.lilly.com</a> or <a href="https://www.ozempic.com/savings-and-resources/save-on-ozempic.html" target="_blank" rel="noopener">ozempic.com</a>.</p> <p><strong>2. Use LillyDirect or NovoCare for self-pay.</strong> If you're uninsured, LillyDirect offers tirzepatide vials at $499/month, and NovoCare offers Ozempic at $349–$499/month — both significantly below list price.</p> <p><strong>3. Compare pharmacies with a free discount card.</strong> Use our <a href="/savings">RxGo savings tool</a> to compare real-time prices at CVS, Walgreens, Walmart, Costco, and independent pharmacies near you. Prices can vary by $100–$200/month for the same drug at different pharmacies.</p> <p><strong>4. Check patient assistance programs.</strong> Both Eli Lilly and Novo Nordisk offer patient assistance programs for uninsured patients who meet income requirements. Apply at <a href="https://www.lillycares.com" target="_blank" rel="noopener">LillyCares.com</a> or <a href="https://www.novocare.com" target="_blank" rel="noopener">NovoCare.com</a>.</p> <p>For a broader look at prescription drug savings strategies, see our guide to <a href="/blog/how-to-save-on-prescriptions">How to Save on Prescriptions</a>.</p> <h2>The Bottom Line</h2> <p>Mounjaro and Ozempic are both highly effective medications for type 2 diabetes, and both produce meaningful weight loss. The clinical evidence favors tirzepatide for greater weight loss and A1C reduction. Semaglutide holds an advantage for patients with established cardiovascular disease, where its MACE-reduction benefit is proven. Cost-wise, both drugs are similarly priced at list, but the self-pay landscape slightly favors Ozempic through NovoCare's transparent pricing program.</p> <p>The decision between them should be made with your prescriber based on your full medical history, insurance coverage, and treatment goals — not on advertising or social media trends. Both drugs are tools; the right tool depends on the job.</p>